Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Related ABT
Benzinga's M&A Chatter for Thursday August 27, 2015
Benzinga's Volume Movers
XOMA Shoots up on Immuno-Oncology Deal with Novartis (Zacks)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Latest Ratings for ABT

Aug 2015Credit SuisseAssumesOutperform
Aug 2015JefferiesMaintainsHold
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (ABT)

Get Benzinga's Newsletters